The Conversation (0)
Realm Therapeutics Announces Completion of $26 million Private Placement
Oct. 12, 2017 09:58AM PST
Biotech InvestingRealm Therapeutics plc (AIM: RLM) has announced the private placement of $26 million, previously disclosed September 21, was approved by its shareholders at a general meeting in London on October 9. As quoted in the press release: The 66,396,485 new ordinary shares issued by the Company in the PIPE were admitted to trading on AIM, …
Realm Therapeutics plc (AIM: RLM) has announced the private placement of $26 million, previously disclosed September 21, was approved by its shareholders at a general meeting in London on October 9.
As quoted in the press release:
The 66,396,485 new ordinary shares issued by the Company in the PIPE were admitted to trading on AIM, a market operated by the London Stock Exchange, on October 10, 2017. US and UK healthcare specialist funds that participated in the PIPE included OrbiMed, BVF Partners LP, RA Capital Management, Abingworth BioEquities Master Fund Ltd and Polar Capital.
Enquiries: Realm Therapeutics plc +44 (0) 20 3727 1000 Alex Martin, Chief Executive Officer Marella Thorell, Chief Financial Officer and Chief Operating Officer FTI Consulting +44 (0) 20 3727 1000 Simon Conway / Mo Noonan N+1 Singer (Nominated Adviser and Broker) +44 (0) 20 7496 3000 Aubrey Powell / Lauren Kettle